8-K: Moleculin Biotech Receives EMA Approval to Expand Phase 3 MIRACLE Clinical Trial in Europe

Moleculin Biotech's Phase 3 MIRACLE trial for Annamycin in R/R AML receives EMA approval, expanding the trial to nine additional EU countries.

Summary

• Moleculin Biotech announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA) for the Phase 2B/3 MIRACLE trial of Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML).
• The trial is approved in all nine EU countries submitted: Belgium, Czechia, France, Germany, Italy, Lithuania, Poland, Romania, and Spain.
• The MIRACLE trial is a global approval trial with sites in the US, Europe, and the Middle East.
• The study is a Phase 2B/3 clinical trial, combining data from both phases to measure the primary efficacy endpoint.
• The trial utilizes an adaptive design, randomizing the first 75 to 90 subjects in Part A to receive high dose cytarabine (HiDAC) combined with either placebo, 190 mg/m2 of Annamycin, or 230 mg/m2 of Annamycin.
• Preliminary primary efficacy data (Complete Remission or CR) and safety/tolerability will be unblinded at 45 subjects, with a second unblinding expected at the conclusion of Part A (75-90 subjects).
• The company expects to reach the first unblinding (45 subjects) in the second half of 2025, and the second unblinding in the first half of 2026.
• Approximately 220 additional subjects will be randomized in Part B of the trial to receive either HiDAC plus placebo or HiDAC plus the optimum dose of Annamycin (randomized 1:1).
• Patient dosing has commenced, and the initial data readout is on track for the second half of 2025.

Sentiment

Score: 7

Explanation: The announcement is positive due to the EMA approval and expansion of the clinical trial, but tempered by the need for additional financing and potential regulatory hurdles.

Positives

• EMA approval in all nine submitted EU countries indicates a significant unmet need for better R/R AML treatments.
• The adaptive trial design allows for early unblinding of data, potentially accelerating the development timeline.
• The trial targets venetoclax regimen failures, addressing a critical gap in current treatment options.
• The company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML following a successful Phase 1B/2 study (MB-106), with input from the FDA.

Negatives

• The clinical trial approval with EMA was granted under the condition that the Company present results of appropriate nonclinical GLP studies before initiating the Phase 3 portion (Part B) of the study.
• The company will require significant additional financing to conduct its clinical trials.

Risks

• The company will require significant additional financing to conduct its clinical trials, and there are no commitments for this financing.
• The study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
• There are minor differences between the US and EU protocols with the FDA and EMA, respectively, which the company is working to harmonize.
• The company's ability to secure financing on a timely basis is assumed for the milestones described in the press release.

Future Outlook

Moleculin Biotech anticipates reporting initial data on the first 45 subjects in the MIRACLE trial in the second half of 2025 and expects to reach the second unblinding in the first half of 2026. The company is focused on driving enrollment and patient dosing.

Management Comments

• Walter Klemp, Chairman and CEO of Moleculin, believes that the EMA approval supercharges the company's recruitment potential.
• Mr. Klemp stated that being accepted in all nine countries indicates the magnitude of the need for a better answer for R/R AML patients.
• Mr. Klemp noted that the company is working to harmonize the US and EU protocols as appropriate.

Industry Context

The announcement addresses the unmet need for effective treatments for R/R AML, particularly in patients who have failed venetoclax regimens. The expansion of the MIRACLE trial into Europe positions Moleculin Biotech to potentially capture a larger market share in the R/R AML treatment landscape.

Comparison to Industry Standards

• Annamycin is being developed as a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity, which are common limitations of existing anthracyclines like doxorubicin and daunorubicin.
• The MIRACLE trial's adaptive design is consistent with modern clinical trial methodologies aimed at optimizing treatment efficacy and safety.
• The focus on venetoclax failures aligns with the increasing recognition of resistance mechanisms in AML treatment and the need for alternative therapeutic strategies.

Stakeholder Impact

• Positive for patients with R/R AML who may benefit from a new treatment option.
• Positive for investors due to the expansion of the clinical trial and potential for future revenue.
• Positive for the company as it advances its lead drug candidate towards potential approval.

Next Steps

• Continue enrollment and patient dosing in the MIRACLE trial.
• Submit results of appropriate nonclinical GLP studies before initiating the Phase 3 portion (Part B) of the study.
• Work to harmonize the US and EU protocols with the FDA and EMA.
• Secure additional financing to conduct clinical trials.

Key Dates

Keywords

Annamycin, MIRACLE trial, R/R AML, EMA approval, Clinical trial, Moleculin Biotech, Leukemia, Oncology